{
    "clinical_study": {
        "@rank": "3156", 
        "acronym": "TRACERx", 
        "arm_group": {
            "arm_group_label": "NSCLC eligible for primary surgery"
        }, 
        "biospec_descr": {
            "textblock": "tissue, blood, plasma and serum"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "To study the NSCLC evolutionary genomic landscape between primary and metastatic sites and\n      the dynamics of intratumour heterogeneity over time combined with detailed clinical,\n      histopathological and cancer phenotypic annotation for each patient, in order to\n      significantly improve the outcomes of NSCLC patients (e.g. reduce their chance of recurrence\n      and improve survival)."
        }, 
        "brief_title": "TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)", 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written Informed consent\n\n          -  Patients \u226518 years of age, with early stage I-IIIA disease who are eligible for\n             primary surgery (including stage IA; and stage IIIA considered unsuitable for\n             chemoradiation)\n\n          -  Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging\n             necessitating surgery (e.g. diagnosis determined from frozen section in theatre)\n\n          -  Primary surgery in keeping with NICE guidelines planned\n\n          -  Agreement to be followed up in a specialist centre\n\n          -  Performance status 0 or 1\n\n        Exclusion Criteria:\n\n          -  Any other current malignancy or malignancy diagnosed or relapsed within the past 5\n             years (other than non-melanomatous skin cancer and in situ cervical cancer)\n\n          -  Psychological condition that would preclude informed consent\n\n          -  Adjuvant regimen other than platinum-based therapy (if a patient is deemed suitable\n             for adjuvant therapy)\n\n          -  Patients infected with blood borne viruses Hepatitis C, Hepatitis B and/or HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Stage I-IIIA NSCLC eligible for primary surgery"
            }
        }, 
        "enrollment": {
            "#text": "842", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888601", 
            "org_study_id": "TBC"
        }, 
        "intervention": {
            "arm_group_label": "NSCLC eligible for primary surgery", 
            "intervention_name": "No intervention", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "state": "Select region", 
                    "zip": "NW1 2PG"
                }, 
                "name": "University College London Hospitals NHS Foundation Trust"
            }, 
            "investigator": {
                "last_name": "Charles Swanton", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)", 
        "overall_contact": {
            "email": "ctc.tracerx@ucl.ac.uk", 
            "last_name": "Natasha Iles", 
            "phone": "02076799265"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022 Define the relationship between intratumour heterogeneity and clinical outcome following surgery and adjuvant therapy (including relationships between intratumour heterogeneity and clinical disease stage and histological subtypes of NSCLC).", 
            "measure": "Intratumour heterogeneity", 
            "safety_issue": "No", 
            "time_frame": "Year 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888601"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University College, London", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Research UK", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University College, London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}